List of Excipients in Branded Drug SERNIVO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Primus Pharmaceuticals Inc	SERNIVO	betamethasone dipropionate	68040-714	BUTYLATED HYDROXYTOLUENE
Primus Pharmaceuticals Inc	SERNIVO	betamethasone dipropionate	68040-714	CETOSTEARYL ALCOHOL
Primus Pharmaceuticals Inc	SERNIVO	betamethasone dipropionate	68040-714	HYDROXYETHYL CELLULOSE
Primus Pharmaceuticals Inc	SERNIVO	betamethasone dipropionate	68040-714	METHYLPARABEN
Primus Pharmaceuticals Inc	SERNIVO	betamethasone dipropionate	68040-714	MINERAL OIL

Last updated: August 11, 2026

Sernivo is a prescription topical spray containing betamethasone dipropionate 0.05% for plaque psoriasis in patients aged 18 years and older. Its commercial differentiation comes from delivery format rather than a new active ingredient: the spray enables rapid application over scalp and hair-bearing skin while avoiding the handling limitations of ointments and creams. The strongest excipient opportunities are low-residue solvent systems, sprayability, skin tolerability, packaging compatibility, and reformulation into nonflammable or cosmetically improved platforms.

Sernivo Excipient Strategy and Commercial Opportunities

What is Sernivo and how is it positioned commercially?

Sernivo is a topical corticosteroid spray approved by the U.S. Food and Drug Administration in 2016 under NDA 207962. The active ingredient is betamethasone dipropionate, a high-potency corticosteroid classified as a Class I topical corticosteroid in the United States.[1]

The approved indication is the topical treatment of mild-to-moderate plaque psoriasis in patients 18 years and older. Sernivo is applied as a thin layer to affected skin twice daily for up to four weeks. Treatment is limited to 50 grams per week, and the product should not be used on the face, groin, or axillae.[1]

Attribute	Sernivo
Active ingredient	Betamethasone dipropionate
Strength	0.05%
Dosage form	Topical spray
Indication	Mild-to-moderate plaque psoriasis
Route	Cutaneous
FDA approval	2016
NDA	207962
Approval holder	Promius Pharma, a division associated with Dr. Reddy's Laboratories
Patient population	Adults 18 years and older
Recommended use	Twice daily for up to four weeks
Main commercial distinction	Spray delivery for plaques and hair-bearing areas

Sernivo competes with topical corticosteroid creams, ointments, lotions, foams, solutions, gels, and aerosol sprays. The commercial proposition is strongest where conventional semisolid products are inconvenient, particularly on the scalp, trunk, and other areas covered by hair.

What excipients are used in Sernivo?

Sernivo uses a hydroalcoholic and lipid-containing spray vehicle. The FDA prescribing information identifies the inactive ingredients as diethyl phthalate, isopropyl alcohol, medium-chain triglycerides, oleyl alcohol, polyoxyl 20 cetostearyl ether, and propylene glycol.[1]

Excipient	Functional role in the formulation	Commercial relevance
Isopropyl alcohol	Volatile solvent and drying vehicle	Supports rapid drying and low residue
Propylene glycol	Cosolvent and humectant	Improves solubilization and may enhance skin penetration
Diethyl phthalate	Vehicle and solvent component	Contributes to spray performance and product feel
Medium-chain triglycerides	Lipid vehicle	Supports emolliency and skin deposition
Oleyl alcohol	Emollient and penetration-supporting excipient	Improves spreadability and after-feel
Polyoxyl 20 cetostearyl ether	Nonionic surfactant and solubilizer	Supports formulation uniformity and spray consistency

The formulation balances two conflicting requirements. Betamethasone dipropionate is highly lipophilic and poorly soluble in water, while the product must remain fluid enough for consistent spray delivery. The solvent system therefore needs to maintain drug solubility, prevent crystallization, dry rapidly, and produce a uniform dose across the canister or pump life.

The excipient system also influences patient adherence. A vehicle that dries quickly and leaves limited residue can be commercially preferable to an ointment, particularly for scalp psoriasis. Alcohol can improve drying but may cause stinging on fissured or inflamed skin. Propylene glycol and surfactants can contribute to irritation or sensitization in susceptible patients. These tradeoffs create room for improved formulations.

What excipient strategy supports a competitive Sernivo follow-on?

A follow-on product should target measurable improvements rather than simply duplicate the active ingredient and concentration. The most defensible strategy is a platform built around delivery performance, tolerability, and manufacturing robustness.

1. Reduce irritation while preserving solubility

The current hydroalcoholic system provides rapid evaporation but can sting on compromised skin. Reformulation opportunities include:

• Lowering the alcohol fraction while maintaining betamethasone dipropionate solubility.
• Replacing part of the alcohol with a less irritating volatile solvent.
• Using mixed solvent systems based on glycols, glycol ethers, or pharmaceutically acceptable lipophilic solvents.
• Reducing reliance on propylene glycol if sensitization or irritation becomes a differentiating concern.
• Adding a controlled lipid fraction to improve skin feel without producing visible residue.

Any solvent substitution would require comparative drug solubility, spray-pattern, drying-time, dermal absorption, irritation, sensitization, and stability studies.

2. Improve deposition on hair-bearing skin

Scalp and hair-bearing plaques are a central use case for topical sprays. A successful formulation should wet the skin beneath hair without producing clumping, greasiness, or a strong solvent odor.

Useful formulation variables include:

• Lower viscosity for penetration through hair.
• Controlled surface tension for better skin wetting.
• Fine droplet size with limited airborne drift.
• Reduced oil content if hair greasiness is a concern.
• A spreading system that allows the patient to apply the product without extensive rubbing.

The commercial opportunity is strongest if the product produces a demonstrably better scalp experience than ointments and creams while matching or improving clinical response.

3. Develop a nonflammable delivery platform

Alcohol-containing sprays create flammability and handling restrictions. A nonflammable or low-flammability system could expand use in households, travel, and institutional settings. Potential technologies include:

• Metered-dose mechanical pumps.
• Bag-on-valve systems.
• Compressed-gas delivery.
• Nonflammable propellant systems.
• Foams or low-viscosity emulsions packaged in alternative devices.

The tradeoff is that changing the delivery device may alter droplet size, dose uniformity, evaporation, microbial controls, and container-closure requirements. A device-led reformulation can still create meaningful intellectual-property value if the product demonstrates a distinct spray plume, dose, or deposition profile.

4. Replace or reassess controversial excipients

Diethyl phthalate is an identifiable formulation component and may create commercial or procurement concerns even where the product remains legally approved. A phthalate-free version could be positioned for patients, prescribers, and health systems seeking a revised excipient profile.

A replacement must maintain:

• Betamethasone dipropionate solubility.
• Chemical stability.
• Sprayability.
• Container compatibility.
• Drying time.
• Skin deposition.
• Preservative or microbial protection, where applicable.

The strongest product claim would be a phthalate-free spray with equivalent or improved clinical performance and a better tolerability profile. The label would need to support the revised formulation through an appropriate FDA regulatory pathway.

What formulations are protected by Sernivo-related intellectual property?

The likely commercial protection for Sernivo is centered on the combination of betamethasone dipropionate, a topical spray vehicle, excipient selection, and methods of treating psoriasis with the spray. Protection may cover formulation architecture rather than the active ingredient itself, because betamethasone dipropionate is an established corticosteroid.

Relevant claim categories include:

1. Topical spray compositions containing betamethasone dipropionate.
2. Alcohol and glycol solvent systems.
3. Lipid-containing spray vehicles.
4. Surfactant-assisted solubilization.
5. Methods of treating plaque psoriasis with a spray.
6. Use on scalp or hair-bearing skin.
7. Spray packaging, metering, or delivery parameters.
8. Stability or crystallization control.

The original active-ingredient patent estate is not the principal barrier. The more relevant barriers are formulation patents, method-of-use patents, regulatory exclusivity, and the difficulty of demonstrating pharmaceutical equivalence for a complex topical spray.

A commercial assessment should distinguish between:

• Patents listed in the FDA Orange Book.
• Unlisted formulation or process patents.
• Continuation applications.
• Expired or abandoned patent families.
• Patent rights covering the device or container.
• Trade secrets involving manufacturing and filling conditions.

The Orange Book is the controlling source for listed patents and exclusivity associated with an approved NDA. The FDA label confirms NDA 207962 and the approved formulation but does not, by itself, establish the full patent position.[1,2]

When does Sernivo lose exclusivity?

Sernivo received FDA approval in 2016. Any new chemical entity exclusivity would not apply because betamethasone dipropionate was previously approved. The product could receive other regulatory exclusivity associated with a new dosage form or formulation, but the duration and scope depend on FDA classification and the specific approval basis.

The main commercial loss-of-exclusivity variables are:

Exclusivity element	Relevance to Sernivo
Active-ingredient patent term	Limited because betamethasone dipropionate is an established drug
Formulation patents	Potentially important if listed or enforceable
Method-of-use patents	May affect psoriasis treatment claims
Three-year clinical-investigation exclusivity	Potentially relevant to a new formulation or dosage form
Pediatric exclusivity	Could add six months if separately awarded
Hatch-Waxman litigation	Relevant if an ANDA applicant files a Paragraph IV certification
Device protection	May delay direct substitution but does not necessarily block all topical alternatives

A generic applicant may challenge listed patents through a Paragraph IV certification. The NDA holder can then file an infringement action within 45 days, triggering a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.[3]

Because topical sprays can require complex comparative studies, generic entry may occur later than the nominal patent expiration date even when the active ingredient is old. The practical barrier is pharmaceutical equivalence: the applicant must establish matching strength, dosage form, route, and performance characteristics, including spray delivery and drug release.

How strong is the Sernivo patent estate?

Sernivo’s patent strength is likely moderate rather than broad. The active ingredient provides limited exclusivity because it is an established corticosteroid. The defensible value lies in narrower formulation and delivery claims.

Patent-estate factor	Assessment
Active ingredient	Weak exclusivity because of long-established use
Spray dosage form	Moderate value if claims cover a specific composition or device
Excipient combination	Moderate to strong if the combination produces unexpected stability or delivery results
Method of use	Moderate, but vulnerable to skinny-label strategies
Manufacturing process	Potentially strong if difficult to reverse engineer
Device configuration	Useful against close copies, less effective against alternative delivery systems
Biosimilar protection	Not relevant because Sernivo is a small-molecule drug
Generic substitution risk	Moderate, depending on listed patents and FDA product-specific requirements

A strong follow-on strategy would build a layered estate covering the composition, excipient alternatives, device, manufacturing process, and clinical use. Narrow claims based only on individual excipients are more vulnerable to design-around strategies.

What generic entry risks exist for Sernivo?

The principal threat is a topical generic or authorized generic with a different excipient system but equivalent active ingredient and dosage form. Potential entrants could pursue:

• A direct spray equivalent.
• A solution or lotion alternative.
• A foam or gel for the same indication.
• A scalp-focused product.
• A betamethasone dipropionate product with a different delivery device.
• A lower-cost formulation marketed under a different label strategy.

A direct spray generic would face the highest technical burden but would pose the greatest substitution risk. A different dosage form could compete clinically without requiring a full copy of Sernivo’s excipients.

The most important defensive assets are:

• Proven scalp and hair-bearing-site performance.
• Better tolerability data.
• A well-characterized spray device.
• Patent claims covering alternative solvent and lipid systems.
• Prescriber familiarity.
• Payer positioning based on adherence or total treatment cost.

What commercial opportunities exist for Sernivo excipient innovation?

Phthalate-free reformulation

A phthalate-free spray could address procurement and patient-perception concerns while preserving the product’s core delivery advantage. This is a formulation opportunity with potential for a 505(b)(2) strategy if the revised product relies partly on the reference product’s safety and efficacy data.[4]

Lower-irritation scalp spray

A vehicle with less alcohol, reduced sting, and improved odor could target patients who discontinue topical corticosteroids because of sensory or tolerability problems. The commercial case would require controlled evidence, not only a revised ingredient list.

Metered-dose spray

A metered-dose pump could improve dose consistency and reduce waste. It could also support a distinct patent estate around dose delivery and application technique.

Combination therapy

Sernivo’s corticosteroid platform could be combined with an established psoriasis ingredient, subject to clinical and regulatory requirements. Potential concepts include combinations with vitamin D analogs, keratolytics, or antimicrobial components for selected dermatologic use cases. Combination products face greater development complexity but may create more defensible differentiation.

International expansion

Sernivo’s spray concept may have opportunities in markets where scalp psoriasis is underpenetrated by topical therapy. Geographic expansion would require review of local corticosteroid potency classifications, excipient restrictions, device rules, and pharmaceutical equivalence standards. Diethyl phthalate and alcohol content may receive different regulatory treatment across jurisdictions.

What is the FDA regulatory pathway for a Sernivo follow-on?

A reformulated betamethasone dipropionate spray could potentially use a 505(b)(2) application if the sponsor relies on FDA findings for the reference product while submitting new data for the changed formulation or device.[4] A conventional ANDA would be more suitable for a product that meets the applicable generic requirements for pharmaceutical equivalence and bioequivalence.

Key development studies would include:

• Assay and impurity profiling.
• Spray-pattern and plume characterization.
• Delivered-dose uniformity.
• Droplet-size distribution.
• Container-closure compatibility.
• In-use stability.
• Freeze-thaw and accelerated stability.
• Dermal irritation and sensitization.
• Comparative skin deposition.
• Pharmacokinetic or pharmacodynamic equivalence, where required.
• Clinical efficacy and safety for a materially changed formulation.

The regulatory route depends on the extent of formulation and device change. A simple excipient substitution may still require substantial evidence if it alters drug delivery, absorption, or local tolerability.

How does Sernivo compare with competing topical corticosteroids?

Product category	Main advantage	Main limitation versus Sernivo
Ointment	High occlusivity and strong skin hydration	Greasy, difficult on hair-bearing areas
Cream	Familiar, broadly accepted vehicle	May require rubbing and can be less effective through hair
Lotion	Lightweight and spreadable	May run or provide less occlusion
Foam	Good scalp usability and rapid application	Often higher manufacturing and packaging complexity
Solution	Easy scalp application	May sting and provide limited emolliency
Spray	Rapid application, low rubbing burden	Alcohol sensitivity, flammability, device complexity

Sernivo’s closest commercial competitors are other high-potency topical corticosteroid sprays, solutions, foams, and scalp products. Its advantage is strongest when application convenience drives adherence. Its vulnerability is the availability of lower-cost formulations containing the same or similar corticosteroid.

Key Takeaways

• Sernivo is a betamethasone dipropionate 0.05% topical spray approved for adult plaque psoriasis.
• Its excipient system uses isopropyl alcohol, propylene glycol, diethyl phthalate, medium-chain triglycerides, oleyl alcohol, and polyoxyl 20 cetostearyl ether.
• The core commercial value is spray delivery for scalp and hair-bearing psoriasis, not novelty of the active ingredient.
• The strongest reformulation opportunities are phthalate-free vehicles, reduced-irritation systems, nonflammable packaging, and metered-dose delivery.
• The patent estate is likely more dependent on formulation, device, manufacturing, and method-of-use claims than on active-ingredient protection.
• Generic risk is moderate because topical spray equivalence can be technically difficult, but the active ingredient is established and vulnerable to formulation workarounds.
• A 505(b)(2) pathway may be suitable for a materially improved formulation or delivery device, while an ANDA may apply to a sufficiently equivalent generic spray.
• Sernivo has no biosimilar risk because betamethasone dipropionate is a small-molecule drug.

FAQs on Sernivo excipients and market strategy

Is Sernivo a steroid spray?

Yes. Sernivo is a high-potency topical corticosteroid spray containing betamethasone dipropionate 0.05%.

Does Sernivo contain alcohol?

Yes. The approved formulation contains isopropyl alcohol, which supports rapid drying but may cause stinging on irritated or fissured skin.[1]

Could a phthalate-free Sernivo competitor be developed?

Yes. A phthalate-free reformulation is technically plausible, but the substitute must preserve drug solubility, stability, spray performance, skin deposition, and regulatory comparability.

Is Sernivo eligible for biosimilar competition?

No. Biosimilar pathways apply to biological products. Sernivo contains the small-molecule active ingredient betamethasone dipropionate, so competition would generally arise through generic, 505(b)(2), or other small-molecule pathways.

What is the most attractive commercial niche for a Sernivo follow-on?

The strongest niche is a low-irritation, phthalate-free, nonflammable, metered-dose scalp spray that maintains rapid drying and minimizes residue on hair.

References

1. U.S. Food and Drug Administration. (2016). Sernivo (betamethasone dipropionate) spray, 0.05% prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.